- Home
- QURE vs EMBC Comparison
QURE vs EMBC Comparison
Compare QURE & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- EMBC
- Stock Information
- Founded
- QURE 1998
- EMBC 1924
- Country
- QURE Netherlands
- EMBC United States
- Employees
- QURE N/A
- EMBC N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- EMBC Medical/Dental Instruments
- Sector
- QURE Health Care
- EMBC Health Care
- Exchange
- QURE Nasdaq
- EMBC Nasdaq
- Market Cap
- QURE 866.3M
- EMBC 782.5M
- IPO Year
- QURE 2007
- EMBC N/A
- Fundamental
- Price
- QURE $70.00
- EMBC $14.02
- Analyst Decision
- QURE Strong Buy
- EMBC Buy
- Analyst Count
- QURE 12
- EMBC 2
- Target Price
- QURE $69.67
- EMBC $18.50
- AVG Volume (30 Days)
- QURE 2.6M
- EMBC 318.1K
- Earning Date
- QURE 10-29-2025
- EMBC 11-25-2025
- Dividend Yield
- QURE N/A
- EMBC 4.28%
- EPS Growth
- QURE N/A
- EMBC 18.26
- EPS
- QURE N/A
- EMBC 1.42
- Revenue
- QURE $14,337,000.00
- EMBC $1,102,500,000.00
- Revenue This Year
- QURE N/A
- EMBC N/A
- Revenue Next Year
- QURE $229.18
- EMBC N/A
- P/E Ratio
- QURE N/A
- EMBC $9.87
- Revenue Growth
- QURE N/A
- EMBC N/A
- 52 Week Low
- QURE $5.35
- EMBC $9.20
- 52 Week High
- QURE $71.50
- EMBC $21.48
- Technical
- Relative Strength Index (RSI)
- QURE 71.31
- EMBC 49.74
- Support Level
- QURE $58.05
- EMBC $13.93
- Resistance Level
- QURE $64.75
- EMBC $14.43
- Average True Range (ATR)
- QURE 4.18
- EMBC 0.46
- MACD
- QURE -0.71
- EMBC 0.03
- Stochastic Oscillator
- QURE 89.18
- EMBC 63.45
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.